We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




PerkinElmer Collaborates on Preterm Birth Biomarkers

By HospiMedica staff writers
Posted on 21 Aug 2006
PerkinElmer, Inc. More...
(Wellesley, MA, USA) has announced a multi-year license-and-research agreement with the University of Leicester (Leicester, United Kingdom) under which the two organizations will begin to lay the groundwork for the clinical investigation and discovery of biomarkers that predict preterm birth (PTB). The collaboration will be financed by PerkinElmer.

PerkinElmer will support the expansion of the University of Leicester's maternal health research capabilities and provide advanced tools, technology, and expertise. Professor J. C. Konje, M.D., and colleagues of Leicester University's reproductive sciences section of the department of cancer studies and molecular medicine are dedicated to the study and prediction of preterm birth. The team is conducting research in the field of preterm labor diagnosis.

The partnership will give PerkinElmer broader access within Professor Konje's research group to clinical samples, methodology, and clinical consultancy support in the field of maternal health. The University of Leicester and PerkinElmer will work towards validating any new PTB biomarkers that will complement PerkinElmer's maternal health portfolio. PerkinElmer and the University of Leicester will share access to licensed intellectual property from new PTB biomarkers that result from this research.

It is estimated that preterm labor complicates 6-10% of all pregnancies and is the most common cause of neonatal morbidity and mortality. Worldwide statistics reflect that there may be as many as 13 million preterm births annually, and this figure is predicted to increase. In the United States alone, an estimated U.S.$820 million is spent on preterm hospitalization subsequently shown to have been unnecessary. These hospitalizations tax both the mother's health and healthcare resources.

Currently, there are no rapid or accurate tests that positively predict preterm labor. The aim of the collaboration between PerkinElmer and the University of Leicester is to effectively address this need and eventually design and supply an effective preterm labor test predictor.



Related Links:
PerkinElmer
University of Leicester

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.